Screnci, M.; Puechmaille, M.; Berton, Q.; Khalil, T.; Mom, T.; Coll, G.
Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation. J. Clin. Med. 2024, 13, 7488.
https://doi.org/10.3390/jcm13237488
AMA Style
Screnci M, Puechmaille M, Berton Q, Khalil T, Mom T, Coll G.
Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation. Journal of Clinical Medicine. 2024; 13(23):7488.
https://doi.org/10.3390/jcm13237488
Chicago/Turabian Style
Screnci, Melina, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll.
2024. "Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation" Journal of Clinical Medicine 13, no. 23: 7488.
https://doi.org/10.3390/jcm13237488
APA Style
Screnci, M., Puechmaille, M., Berton, Q., Khalil, T., Mom, T., & Coll, G.
(2024). Bevacizumab for Vestibular Schwannomas in Neurofibromatosis Type 2: A Systematic Review of Tumor Control and Hearing Preservation. Journal of Clinical Medicine, 13(23), 7488.
https://doi.org/10.3390/jcm13237488